Rothschild Capital Partners LLC Decreases Position in Medtronic plc (NYSE:MDT)

Rothschild Capital Partners LLC lessened its stake in Medtronic plc (NYSE:MDT - Free Report) by 90.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,786 shares of the medical technology company's stock after selling 33,933 shares during the period. Rothschild Capital Partners LLC's holdings in Medtronic were worth $302,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Morse Asset Management Inc purchased a new stake in shares of Medtronic during the 3rd quarter valued at $225,000. Te Ahumairangi Investment Management Ltd raised its position in Medtronic by 4.1% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 52,321 shares of the medical technology company's stock worth $4,684,000 after purchasing an additional 2,050 shares during the period. Chelsea Counsel Co. purchased a new position in Medtronic in the 3rd quarter worth $45,000. Tudor Financial Inc. purchased a new position in Medtronic in the 3rd quarter worth $586,000. Finally, Anchor Investment Management LLC raised its position in Medtronic by 1.2% in the 3rd quarter. Anchor Investment Management LLC now owns 107,518 shares of the medical technology company's stock worth $9,680,000 after purchasing an additional 1,271 shares during the period. Institutional investors own 82.06% of the company's stock.

Medtronic Trading Down 0.2 %

Shares of MDT traded down $0.18 during trading hours on Monday, reaching $83.98. 4,513,345 shares of the company traded hands, compared to its average volume of 6,676,670. Medtronic plc has a 12 month low of $75.96 and a 12 month high of $96.25. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.48. The company's fifty day moving average price is $88.14 and its two-hundred day moving average price is $87.25. The company has a market capitalization of $107.71 billion, a price-to-earnings ratio of 25.53, a price-to-earnings-growth ratio of 2.22 and a beta of 0.79.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The medical technology company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.36 by $0.03. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. The business had revenue of $8.29 billion for the quarter, compared to analyst estimates of $8.33 billion. Equities research analysts predict that Medtronic plc will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 3.33%. The ex-dividend date of this dividend was Friday, March 28th. Medtronic's payout ratio is currently 85.11%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MDT. Royal Bank of Canada reiterated an "outperform" rating and issued a $105.00 target price on shares of Medtronic in a research report on Wednesday, February 19th. UBS Group lifted their target price on shares of Medtronic from $85.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. Truist Financial decreased their target price on shares of Medtronic from $93.00 to $90.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a report on Wednesday, February 19th. Finally, Robert W. Baird raised their price target on shares of Medtronic from $90.00 to $91.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $96.14.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.